A View LCS vs ClearRead CT
AI Verdict
Choose A View LCS if…
Choose AVIEW LCS if your practice requires a single, comprehensive AI platform for multi-faceted thoracic CT analysis, including detailed emphysema quantification and advanced coronary artery calcification scoring beyond basic Agatston. This tool is ideal for clinics seeking automated, in-depth reporting and precise 3D nodule volume quantification from a single low-dose CT scan, offering a holistic view of thoracic health.
View A View LCS →Choose ClearRead CT if…
Choose ClearRead CT if your primary goal is to significantly enhance pulmonary nodule detection accuracy and reduce reading times through advanced AI and patented vessel suppression technology. This solution is particularly well-suited for workflows that prioritize efficient nodule characterization, automated tracking against prior exams, and seamless PACS integration to streamline radiology operations.
View ClearRead CT →When choosing between AVIEW LCS and ClearRead CT, physicians should consider their primary focus in thoracic CT analysis. AVIEW LCS excels in comprehensive thoracic CT analysis from a single low-dose CT scan, offering detailed lung cancer screening, emphysema quantification, and coronary artery calcification detection. Its key features include automated lung nodule detection and classification with 3D volume quantification, Lung-RADS scoring, and advanced emphysema analysis. It also provides robust coronary artery calcium scoring and segmentation of major coronary arteries, alongside automated comprehensive report generation. AVIEW LCS offers flexible deployment options, including cloud, hybrid, and on-premise solutions.
ClearRead CT, on the other hand, specializes in enhancing pulmonary nodule detection and coronary artery calcification analysis with a strong emphasis on improving diagnostic accuracy and reducing reading times. A key practical difference is its patented Vessel Suppression technology, which aims to provide clearer visualization for nodule detection. ClearRead CT focuses on nodule characterization, measurement, and automated tracking compared to prior exams. While both tools offer CAC scoring, ClearRead CT highlights its ability to do so on ungated, non-contrast CTs. Deployment for ClearRead CT is available on-premise and in the cloud.
Physicians prioritizing a holistic thoracic assessment with detailed quantification for lung cancer screening and emphysema, alongside cardiac risk assessment, may find AVIEW LCS more aligned with their needs. Its comprehensive reporting and diverse deployment options could be beneficial for various practice settings. Conversely, if the primary goal is to optimize pulmonary nodule detection accuracy and streamline radiology workflows with advanced vessel suppression technology to reduce reading times, ClearRead CT would be the more suitable choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | A View LCS | ClearRead CT |
|---|---|---|
| Pricing | Contact for quote | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | On-premise (stand-alone server, virtual machine) and Cloud |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ClearRead CTClearRead CT (Tool B) explicitly highlights 'Reduced Reading Time (up to 36%)' and 'Seamless PACS Integration / Vendor-neutral processing,' with studies confirming its ability to integrate into existing workflows without requiring radiologists to open a second application. While A View LCS (Tool A) also aims to reduce workload and automate reporting, Tool B's direct quantification of efficiency gains and emphasis on seamless integration into daily radiology practice gives it an edge in practical usability.
Clinical Value
ClearRead CTBoth tools are FDA-cleared and offer robust features for lung nodule detection and CAC scoring. ClearRead CT (Tool B) provides strong evidence of 'Improved Detection Accuracy (29% reduction in missed actionable nodules)' and its patented vessel suppression technology directly enhances visualization. Furthermore, a comparative study indicated ClearRead CT CAC had the 'most reliable performance for both scoring and risk stratification' among FDA-approved AI algorithms.
Pricing & Value
TieBoth A View LCS (Tool A) and ClearRead CT (Tool B) state that pricing information is available upon contact and is not publicly disclosed. Without transparent pricing details or specific value-for-money metrics for either tool, it is impossible to conduct a head-to-head comparison of their pricing structures or assess their relative value.
Enterprise Readiness
A View LCSA View LCS (Tool A) explicitly states it is HIPAA compliant and has a BAA available in its structured facts, offering clear assurances for enterprise deployment. It also provides a wider range of deployment options, including cloud, hybrid, dedicated hardware, and virtualized environments (VM, Docker). While ClearRead CT (Tool B) is ISO27001 certified and operates with large institutions, its compliance claims for BAA and HIPAA are stated as 'likely' and require vendor contact.
Innovation
ClearRead CTClearRead CT (Tool B) stands out with its 'Patented Vessel Suppression (Clear Visual Intelligence)' technology, which was a pioneering and first FDA-cleared innovation for concurrent reading to improve nodule conspicuity. While A View LCS (Tool A) offers innovative features like CT kernel conversion AI and comprehensive thoracic analysis including ILD and COPD, the foundational and patented nature of ClearRead CT's vessel suppression represents a distinct and impactful technological advancement.
Support & Docs
ClearRead CTClearRead CT (Tool B) provides comprehensive support information, including direct contact details for customer care, FAQs, system requirements, workflow guides, and accessible user manuals and documentation online. A View LCS (Tool A) does not provide specific details regarding its support channels or documentation in the provided information or search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | A View LCS | ClearRead CT |
|---|---|---|
| Product Name | A View LCS | ClearRead CT |
| Company | Coreline Soft Co. | RIVERAIN TECHNOLOGIES |
| Tagline | AI-powered medical imaging for comprehensive thoracic disease diagnosis. | AI-Driven Clarity for Faster & More Confident Nodule Detection |
| Key Features (Nodule Analysis) | Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Lung-RADS scoring and reporting | Pulmonary Nodule Detection (solid, part-solid, ground glass), Nodule Characterization and Measurement (volume, diameter, location, type, depth), Automated Nodule Tracking and Comparison to Prior Exams |
| Key Features (Cardiac Analysis) | Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass), Segmentation of major coronary arteries | Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs) |
| Key Features (Other) | Emphysema analysis and quantification (LAA), Automated comprehensive report generation (PDF, DICOM PDF, SR), CT kernel conversion AI technology | Patented Vessel Suppression (Clear Visual Intelligence), Reduced Reading Time (up to 36%), Improved Detection Accuracy (29% reduction in missed actionable nodules), Seamless PACS Integration / Vendor-neutral processing |
Videos
Demos, reviews, and walkthroughs featuring A View LCS and ClearRead CT.